Articles and Presentations Featuring or Mentioning Rebiotix Inc., a Ferring Company
Practical Advice on Novel Fecal Microbiota Transplantation in CDI
Practical considerations for the future use of novel FMT therapy for patients with recurrent Clostridioides difficile infection.
Results of the PUNCH CD3 Trial: RBX2660 in Recurrent CDI
Shared insight on the phase 3 data behind RBX2660, a novel FMT therapy for patients with recurrent Clostridioides difficile infection.
New Product in Development Looks to Help Patients with Clostridium difficile (video interview with Lee Jones, the President and CEO of Rebiotix and Erik Dubberke, MD, from the University of Washington School of Medicine during the annual ID Week conference in San Diego)
By providing links to other websites, Rebiotix, Inc. does not guarantee, approve or endorse the information or products available at these websites, nor does a hyperlink indicate any association with or endorsement by the hyperlinked site to Rebiotix, Inc.